In the ongoing clinical trial in ER+ breast cancer patients, zotatifin in combination with either fuvelstrant or fulvestrant and abemaciclib were well tolerated, with most adverse effects being grade 1/2 (51). Here, ESR1 is linked to breast carcinoma.